Hemorrhoid Drugs Market Share

Regionally, the global hemorrhoid drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.

Europe Market Statistics

Europe industry is expected to dominate majority revenue share by 2036, on the back of high geriatric population, coupled with availability of advanced treatment options, better reimbursement policies and fast commercialization of novel products. The EU includes 27 countries, including France, Belgium, Germany, and Luxemburg among others. Moreover, presence of well-established healthcare infrastructure and high disposable income in the region are anticipated to propel the growth of the hemorrhoid drugs market in the region.

APAC Market Analysis

The hemorrhoid drugs market in the Asia Pacific is estimated to witness the highest CAGR during the forecast period, owing to the increasing population, growing healthcare sector, and emerging pharmaceutical companies.

Frequently Asked Questions (FAQ)

Growing prevalence of piles or hemorrhoids on the back of poor diet, lifestyle diseases and obesity, is the major factor driving the market growth.

The market is anticipated to attain a robust CAGR over the forecast period, i.e., 2021-2029.

Social shame and stigma related to hemorrhoids is a major factor estimated to hamper the market growth.

The market in Europe will provide the highest growth opportunities for the market during the forecast period on the back of increasing geriatric population and improving healthcare sector.

The major players in the market are Taro Pharmaceutical Industries Ltd., AstraZeneca, The Himalaya Drug Company, Panacea Biotec Ltd., Abbott Healthcare Private Limited, Sanofi-aventis Groupe, Pfizer Inc., Purdue Pharma L.P and others.

Hemorrhoid Drugs Market Share